BioCentury | May 4, 2018
Clinical News

Mithra's Donesta meets in Phase II for postmenopausal vasomotor symptoms

...to severe vasomotor symptoms from baseline to week 12 vs. placebo (80% vs. 60%, p<0.05). Mithra...
...Menopause Society meeting in Vancouver in June. Donesta comprises estetrol (E4), a human fetal steroid. Mithra Pharmaceuticals S.A....
...patient satisfaction and safety Status: Phase II data Milestone: Additional Phase II data (6/2018) Jaime De Leon Donesta Mithra Pharmaceuticals S.A....
BioCentury | Oct 20, 2017
Clinical News

Mithra completes enrollment in Phase II trial of Donesta for vasomotor menopausal symptoms

...top-line data in late 1Q18. Donesta is an oral estetrol (E4), a human fetal steroid. Mithra Pharmaceuticals S.A....
...metabolism and bone metabolism markers Status: Completed Phase II enrollment Milestone: Phase II data (1Q18) Allison Johnson Donesta Mithra Pharmaceuticals S.A. E4...
BioCentury | Jul 6, 2017
Company News

Mithra grants Fuji commercialization rights to Donesta in Asia

...estetrol is in Phase II to treat vasomotor menopause symptoms, with top-line data expected 1Q18. Mithra...
...is eligible for development, regulatory and commercialization milestones in the low, double-digit millions. Fuji and Mithra...
...Phase III development of the candidate in Japan. The companies did not respond to inquiries. Mithra Pharmaceuticals S.A....
BioCentury | Jul 6, 2017
Financial News

Mithra raises €26.1M in private placement

...On June 21, women’s health company Mithra Pharmaceuticals S.A (Euronext:MITRA) raised €26.1 million ($29.2 million) through...
...underwritten by KBC Securities , Degroof Petercam and Kempen & Co. Mithra Pharmaceuticals S.A. (Euronext:MITRA), Liege, Belgium Alicia Parker Mithra Pharmaceuticals S.A....
BioCentury | May 18, 2006
Financial News

MacroGenics raises $45 million

...Idec New Ventures joined existing investors Texas Pacific Group; Alta Partners; InterWest Partners; MPM Capital; Mithra...
BioCentury | Oct 18, 2004
Finance

Ebb & Flow

...treatment for WNV and a treatment for lymphoma. MacroGenics investors were Alta Partners; TPG Ventures; Mithra...
BioCentury | Oct 15, 2004
Financial News

MacroGenics raises $30.5 million

...in a series B round led by Alta Partners and TPG Ventures. Other investors included Mithra...
BioCentury | Mar 15, 2004
Finance

Ebb & Flow

...prior to the IPO); Atlas Venture Partners (19.2%); MVM International (14.1%); Cardinal Partners (10.9%); and Mithra...
BioCentury | Mar 12, 2004
Financial News

Momenta files for IPO

...AVE). On March 1, Momenta raised $20.5 million in a series C round. Investors included Mithra...
BioCentury | Mar 1, 2004
Financial News

Momenta raises $20.5 million

...complex sugars and glycosylated biomolecules, raised $20.5 million in a series C round. Investors included Mithra...
Items per page:
1 - 10 of 10
BioCentury | May 4, 2018
Clinical News

Mithra's Donesta meets in Phase II for postmenopausal vasomotor symptoms

...to severe vasomotor symptoms from baseline to week 12 vs. placebo (80% vs. 60%, p<0.05). Mithra...
...Menopause Society meeting in Vancouver in June. Donesta comprises estetrol (E4), a human fetal steroid. Mithra Pharmaceuticals S.A....
...patient satisfaction and safety Status: Phase II data Milestone: Additional Phase II data (6/2018) Jaime De Leon Donesta Mithra Pharmaceuticals S.A....
BioCentury | Oct 20, 2017
Clinical News

Mithra completes enrollment in Phase II trial of Donesta for vasomotor menopausal symptoms

...top-line data in late 1Q18. Donesta is an oral estetrol (E4), a human fetal steroid. Mithra Pharmaceuticals S.A....
...metabolism and bone metabolism markers Status: Completed Phase II enrollment Milestone: Phase II data (1Q18) Allison Johnson Donesta Mithra Pharmaceuticals S.A. E4...
BioCentury | Jul 6, 2017
Company News

Mithra grants Fuji commercialization rights to Donesta in Asia

...estetrol is in Phase II to treat vasomotor menopause symptoms, with top-line data expected 1Q18. Mithra...
...is eligible for development, regulatory and commercialization milestones in the low, double-digit millions. Fuji and Mithra...
...Phase III development of the candidate in Japan. The companies did not respond to inquiries. Mithra Pharmaceuticals S.A....
BioCentury | Jul 6, 2017
Financial News

Mithra raises €26.1M in private placement

...On June 21, women’s health company Mithra Pharmaceuticals S.A (Euronext:MITRA) raised €26.1 million ($29.2 million) through...
...underwritten by KBC Securities , Degroof Petercam and Kempen & Co. Mithra Pharmaceuticals S.A. (Euronext:MITRA), Liege, Belgium Alicia Parker Mithra Pharmaceuticals S.A....
BioCentury | May 18, 2006
Financial News

MacroGenics raises $45 million

...Idec New Ventures joined existing investors Texas Pacific Group; Alta Partners; InterWest Partners; MPM Capital; Mithra...
BioCentury | Oct 18, 2004
Finance

Ebb & Flow

...treatment for WNV and a treatment for lymphoma. MacroGenics investors were Alta Partners; TPG Ventures; Mithra...
BioCentury | Oct 15, 2004
Financial News

MacroGenics raises $30.5 million

...in a series B round led by Alta Partners and TPG Ventures. Other investors included Mithra...
BioCentury | Mar 15, 2004
Finance

Ebb & Flow

...prior to the IPO); Atlas Venture Partners (19.2%); MVM International (14.1%); Cardinal Partners (10.9%); and Mithra...
BioCentury | Mar 12, 2004
Financial News

Momenta files for IPO

...AVE). On March 1, Momenta raised $20.5 million in a series C round. Investors included Mithra...
BioCentury | Mar 1, 2004
Financial News

Momenta raises $20.5 million

...complex sugars and glycosylated biomolecules, raised $20.5 million in a series C round. Investors included Mithra...
Items per page:
1 - 10 of 10